AstraZeneca presents advances in improving treatment options for ovarian and lung cancer patients at ESMO 2018 Congress

More than 50 presentations, including data from the pivotal Phase III trial SOLO-1 selected for oral presentation in the ESMO Presidential Symposium New Lynparza data demonstrate clinically-meaningful improvement for newly-diagnosed, advanced BRCA-mutated ovarian cancer New data in NSCLC improve understanding of resistance mechanisms after 1st-line Tagrisso and evaluate treatment variations prior to Imfinzi in Stage III disease AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the ESMO 2018 Congress (European Society for Medical Oncology) in Munich, Germany, 19-23 October. Data span several tumour types and include full results from the Phase III SOLO-1 ovarian cancer trial to be presented in the Presidential Symposium, along with new research on resistance mechanisms in metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In addition, MedImmune Senior Vice President, Head of Oncology Innovative Medicines and Professor of Medicine and Medical Oncology at South-Paris University, Jean-Charles Soria, will be recognised for his outstanding contribution to medical oncology by receiving the 2018 ESMO Award. Dave Fredrickson, Executive Vice President, Head of Oncology Business Unit, said: “Our diversified Oncology portfolio prioritises medicines with the potential to redefine the clinical practice of cancer treatment. We are working to deliver potentially curative approaches earlier in the treatment paradigm across a range of cancers. We are also exploring how to stay a step ahead of disease progression by understanding how tumours become resistant to treatment over time.” Detailed Lynparza data from the Phase III SOLO-1 trial in women with newly-diagnosed, advanced BRCA-mutated ovarian cancer SOLO-1 is the only trial of a poly (ADP-ribose) polymerase (PARP) inhibitor, Lynparza, to demonstrate a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for women with newly-diagnosed, advanced BRCA -mutated ovarian cancer. Data from the trial by AstraZeneca and MSD, known as Merck in the US and Canada, will be featured in an ESMO Presidential Symposium (Presentation #LBA7_PR). In the 1st-line setting, only 20 percent of women have prolonged, relapse-free periods and are considered cured following surgery and chemotherapy, and 70 percent relapse within three years. These data will provide detailed PFS results for Lynparza, supporting the treatment goal of long-term remission in women with newly-diagnosed disease, where currently-available treatment options aimed at extending time to progression only offer modest improvements. New understanding of acquired resistance mechanisms in lung cancer from the Phase III FLAURA trial Preliminary data on acquired resistance mechanisms seen with 1st-line Tagrisso (osimertinib) use in the Phase III FLAURA trial (Presentation Number #LBA50) will be presented as a late-breaker, providing new insights into potential treatment strategies for patients with metastatic EGFR-mutated NSCLC. Lung cancer Immuno-Oncology (IO): New insights from the Phase III PACIFIC trial An oral presentation of subgroup analyses will explore the efficacy and safety of the PACIFIC regimen in unresectable, Stage III NSCLC evaluating differences in treatment and timing for chemoradiation therapy before Imfinzi (Abstract #1363O). Early pipeline explores combinations in difficult-to-treat tumour types Key presentations from AstraZeneca’s early stage pipeline include insight into novel DNA Damage Response (DDR)-IO combinations. A Phase I clinical and translational evaluation of the ATR inhibitor, AZD6738, in combination with Imfinzi in patients with lung or head and neck cancer will be featured as a poster discussion (Abstract #413PD). Data from the early-stage IO pipeline, including updated results from the Phase Ib/II multi-indication SCORES trial of Imfinzi plus danvatirsen (AZD9150, STAT3) or AZD5069 (CXCR2), demonstrating the impact of targeting novel pathways, will also be presented (Abstract #1044O). Additionally, new approaches to patient selection using different methods of detection of homologous recombination repair gene mutations will be highlighted in a Phase II trial of Lynparza plus abiraterone (Study 08) in metastatic castration-resistant prostate cancer (Abstract #97P). Key AstraZeneca/MedImmune presentations at ESMO 2018: Lead author Abstract title Presentation details Ovarian cancer Moore, K Phase III SOLO1 trial: Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced stage ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm) Oral Presentation Presidential Symposium 2 Sunday 21 st October, 16:30-18:10 Presentation Time: 17:45-18:00 Location: Hall A2, Room 18 Abstract #LBA7_PR Penson, RT MEDIOLA: A Phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in patients with advanced solid tumors – new ovarian cancer cohorts Poster Gynaecological cancers Monday 22 nd October, 12:45-13:45 Location: Hall A3 Abstract #448TiP Colombo, N BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib with continuous schedule vs. cediranib-olaparib with intermittent schedule in advanced platinum-resistant ovarian cancer Poster Gynaecological cancers Saturday 20 th October, 12:30-13:30 Location: Hall A3 Abstract #1002TiP Lung Cancer Ramalingam, S Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study Oral Presentation NSCLC, metastatic Friday 19 th October, 16:00-17:30 Presentation Time: 16:00-16:12 Location: Hall A2, Room 18 Abstract #LBA50 Faivre-Finn, C Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC Oral Presentation​ Non-Metastatic NSCLC and Other Thoracic Malignancies Sunday 21 st October, 09:15-10:45 Presentation Time: 10:15-10:30 Location: Hall A1, Room 17 Abstract #1363O Kowalski, D ARCTIC: durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥3L advanced NSCLC treatment Oral Presentation ​ NSCLC, metastatic Monday 22 nd October, 09:15-11:00​ Presentation Time: 10:15-10:30 Location: Hall A1, Room 17​ Abstract #1378O Bondarenko, I Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from Arm A of the Phase II BALTIC study Poster Discussion Lung early Sunday 21 st October, 14:45-16:00 Discussion Time: 15:25-15:35 Location: ICM, Room 1 Abstract #1665PD Early pipeline Cohen, EW Phase 1b/2 Study (SCORES) of Durvalumab (D) Plus AZD9150 or AZD5069 in Advanced Solid Malignancies and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M-SCCHN): Updated Results Oral Presentation Head & Neck cancer Monday 22 nd October, 14:45-16:15 Presentation Time: 14:45-15:00 Location: ICM, Room 14b Abstract #1044O Krebs, MG Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma Poster Discussion Developmental therapeutics Saturday 20 th October, 15:00-16:15 Discussion Time: 15:00-15:20 Location: Hall B3, Room 22 Abstract #413PD Carr, Thomas H Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC) Poster Biomarkers Saturday 20 th October, 12:30-13:30 Location: Hall A3 Abstract #97P NOTES TO EDITORS About AstraZeneca in Oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology. By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. About MedImmune MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and South San Francisco, CA. For more information, please visit www.medimmune.com . CONTACTS Media Relations Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Matt Kent UK/Global +44 203 749 5906 Gonzalo Viña UK/Global +44 203 749 5916 Jennifer Hursit UK/Global +44 7384 799726 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Josie Afolabi +44 203 749 5631 Craig Marks Finance; Fixed Income +44 7881 615 764 Henry Wheeler Oncology +44 203 749 5797 Christer Gruvris Cardiovascular; Metabolism +44 203 749 5711 Nick Stone Respiratory; Renal +44 203 749 5716 Jennifer Kretzmann Retail Investors +44 203 749 5824 US toll-free +1 866 381 7277 tags Corporate and financial AstraZeneca Websites This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network. Veeva ID: Z4-25396 Date of next review: August 2022 Resources All resources Open Innovation Externally sponsored scientific research Medical Information for HCPs US prescription assistance programmes Global clinical trials information Medicines Report a possible side effect Quick links Media Investor Relations Partnering Careers Sustainability Modern Slavery Statement AZethics – Report A Concern Supplier information Social Media Community Guidelines Social Media LinkedIn Twitter YouTube Instagram Glassdoor Facebook utility links Legal notice and Terms of Use Privacy notice Site map Contact us Cookie policy © AstraZeneca 2021 You are now leaving AstraZeneca.com You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Cancel Continue ? Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. I disagree I agree ? ?

The release as fetched from its publisher. astrazeneca.com ↗